康莱特注射液辅助治疗非小细胞肺癌的系统评价再评价
该研究对12个数据库检索至2022年3月24日的20篇康莱特注射液辅助治疗非小细胞肺癌的系统评价进行再评价,采用PRISMA、AMSTAR、ROBIS和GRADE工具评估质量。结果显示报告质量较完整,但方法学质量极低、偏倚风险高;中等质量证据提示康莱特联合化疗可提高客观缓解率9.7-16.4%、疾病控制率8.1-14%、生活质量20.1-28.6%,并降低胃肠道症状11.5%-23.2%和白细胞减少19.5-29.2%。
要点
- 康莱特联合化疗在中等质量证据下改善ORR、DCR、生活质量和部分不良反应。
- 联合放疗或靶向治疗证据质量低,ORR和生活质量获益数值需谨慎解读。
- 系统评价方法学质量极低、偏倚风险高,临床应用证据尚不明确。
核心结论
- 康莱特注射液联合化疗、放疗或靶向治疗对ORR和生活质量有影响,并诱导白细胞减少、恶心呕吐等不良反应。
- 可能改善患者生存,但其低级别质量对免疫功能的影响尚未确定。
- 由于系统评价和纳入研究报告质量低、方法学质量极低且偏倚风险高,康莱特注射液的临床应用仍不明确。
研究设计与样本
- 系统评价再评价,检索12个数据库、咨询专家并检索会议论文至2022年3月24日。
- 纳入20篇系统评价(13篇中文、7篇英文),第一作者均为中国作者。
- 治疗组为康莱特注射液联合其他治疗,不限制剂量、疗程或联合方案。
- 排除网络荟萃分析和重复数据的系统评价。
- 采用PRISMA 2009、AMSTAR、ROBIS和GRADE工具评估质量,用R进行可视化分析。
主要发现
- 大多数纳入研究报告信息较完整(21-27分),占总文献的四分之三。
- 所有研究的方法学质量均为极低,偏倚风险大多为高。
- 中等质量证据中,康莱特联合化疗较单纯化疗提高ORR 9.7-16.4%(11篇SR)、DCR 8.1-14%(4篇SR)、生活质量20.1-28.6%(12篇SR)。
- 中等质量证据中,胃肠道症状发生率降低11.5%-23.2%(5篇SR),白细胞减少改善19.5-29.2%(4篇SR)。
- 低质量证据中,联合放疗和靶向治疗分别提高ORR 25.9%和16.8%、生活质量31.3%和22.8%。
关键数值与推荐
- 中等质量证据:康莱特联合化疗较单纯化疗提高ORR 9.7-16.4%(11篇SR)。
- 中等质量证据:康莱特联合化疗较单纯化疗提高DCR 8.1-14%(4篇SR)。
- 中等质量证据:康莱特联合化疗较单纯化疗提高生活质量20.1-28.6%(12篇SR)。
- 中等质量证据:胃肠道症状发生率降低11.5%-23.2%(5篇SR),白细胞减少改善19.5-29.2%(4篇SR)。
- 低质量证据:联合放疗和靶向治疗分别提高ORR 25.9%和16.8%、生活质量31.3%和22.8%。
临床怎么用
- 康莱特注射液可作为非小细胞肺癌化疗的辅助治疗,中等质量证据支持其改善ORR、DCR、生活质量和部分不良反应。
- 联合放疗或靶向治疗时证据质量低,临床决策需结合患者具体情况谨慎评估。
- 因系统评价方法学质量极低和偏倚风险高,当前证据尚不足以明确康莱特注射液的临床定位。
局限性
- 纳入的系统评价报告质量虽较完整,但方法学质量均为极低。
- 偏倚风险大多为高,证据质量以低或极低为主。
- 康莱特注射液对免疫功能的影响尚未确定。
- 需要更高质量的系统评价和随机对照试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Kanglaite injection (KLTi), a Chinese herbal medicine, is used as an adjuvant treatment for non-small-cell lung cancer (NSCLC). AIMS OF THE STUDY: To provide an evidence-based endorsement for the clinical application and selection of KLTi by evaluating the reporting quality, methodological quality, risk of bias, and evidence quality of systemic reviews (SRs). MATERIALS AND METHODS: SRs of KLTi adjuvant therapy of NSCLC were searched by using 12 databases, consulting experts, and retrieving relevant conference papers until 2022.03.24. The treatment group received KLTi in combination with other therapies, regardless of dosage, duration, or the therapy combined. Network meta-analyses and SRs using repeated data were excluded. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines 2009, A MeaSurement Tool to Assess systematic Reviews, Risk of Bias in Systematic Review, and the Grading of Recommendations Assessment, Development and Evaluation were used to assess the quality of reports, methodological quality, risk of bias, and level of evidence; R was used for visual analysis of the relevant contents. RESULTS: Twenty SRs (13 Chinese and 7 English articles), all authored by Chinese authors as the first author, were included. The reporting information of most included studies was relatively complete (21-27 points), accounting for three-fourths of the total literature. The quality of the methods used in all studies was critically low. The risk of bias was mostly high. Results of the evidence summary showed that among the "moderate" evidence, KLTi combined with chemotherapy had benefits of 9.7-16.4% for objective response rate (ORR) (11 SRs), 8.1-14% for disease control rate (four SRs), and 20.1-28.6% for quality of life (12 SRs) compared with those of chemotherapy alone. The incidence of gastrointestinal symptoms (five SRs) was reduced by 11.5%-23.2%, while that of leukopenia (four SRs) improved by 19.5-29.2%. Combined radiotherapy and targeted therapy had benefits of 25.9% and 16.8%, respectively, in ORR and 31.3% and 22.8%, respectively, in quality of life (the quality of evidence was "low"). The results depicted that treatment with two courses of KLTi produce the best results. CONCLUSION: Our results suggest that KLTi, whether combined with chemotherapy, radiotherapy, or targeted therapy, has an effect on ORR and quality of life and induces adverse reactions, such as leukopenia, nausea, and vomiting. It may improve patient survival; however, the impact of its low-grade quality on the immune function remains undetermined. Owing to the low reporting quality and methodological quality and high risk of bias of the SRs and the included studies, clinical application of KLTi remains unelucidated; higher-quality SRs and randomized controlled trials are necessary in the future.
引用
- Lu T, Yu J, Gao R, et al. Chinese patent medicine Kanglaite injection for non-small-cell lung cancer: An overview of systematic reviews. J Ethnopharmacol. 2022. PMID: 36240975. doi:10.1016/j.jep.2022.115814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。